Media ReleasesBARD1 Life Sciences

View All BARD1 Life Sciences News


US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis


• US Patent No 11137402 granted covering lung cancer diagnosis
• Protects a BARD1 autoantibody test for diagnosis of lung cancer in key US market

Melbourne, Australia, 12 November 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) announces that US Patent No: 11137402 titled “Lung Cancer Diagnosis” was issued by the United States Patent and Trademark Office.

The issued US 11137402 claims are directed towards methods for detecting antibodies to BARD1 peptides, methods for diagnosing lung cancer and kits for lung cancer diagnosis. The patent application was filed by BARD1AG SA (a fully owned subsidiary of BARD1 Life Sciences Ltd) on 5 November 2014 and is due to expire on 5 February 2035.

CEO Dr Leearne Hinch said: “This patent family enforces intellectual property protection in the US for a potential BARD1-Lung cancer test that detects autoantibodies associated with lung cancer.”

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.